Nephros, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Nephros, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$25For every $100 of sales, $25 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $37 tied up three years earlier.
More money tied up than 53% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$97Sales grew 88% in 3 years; of every extra $100 of sales, $97 became extra profit.
Higher than 80% of Healthcare companies in United States.
Asset Productivity Ratio
+88% / +24%In 3 years sales changed by +88% while total assets changed by +24%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
4.2×Debt due within a year is covered 4.2 times by its yearly operating cash.
Higher than 79% of Healthcare companies in United States.
Cash Cushion Ratio
+11%Cash, after subtracting all debt, equals 11% of its market value (net cash).
Higher than 52% of Healthcare companies in United States.
Tangible Assets Ratio
91%Of every $100 the company owns, $91 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 64% of Healthcare companies in United States.
Tangible Net Worth Ratio
88%Of every $100 of net worth, $88 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 70% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Nephros, Inc. owes $0.24 for every $1 it owns. Net profit rose 1514% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
23.5Investors pay $23.5 for every $1 of Nephros, Inc.'s yearly profit, lower than 57% of Healthcare companies in United States.
P/B ratio
3.19The share price is 3.19 times Nephros, Inc.'s book value per share, higher than 58% of Healthcare companies in United States.
Market cap
$38 MThe total market value of all of Nephros, Inc.'s shares at today's price (share price × number of shares), smaller than 77% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$12 MWhat Nephros, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.10Net worth divided by the number of shares. The share price of $3.52 is 3.2 times this, which is the P/B above.
Return on equity (ROE)
16.1%Nephros, Inc. earned 16.1% on its shareholders' money over the last year, higher than 88% of Healthcare companies in United States.
Owes vs Owns
0.24×Nephros, Inc. owes $0.24 for every $1 it owns (low), lower than 67% of Healthcare companies in United States.
Dividend yield
NoneNephros, Inc. does not currently pay a dividend.
Revenue growth
+33%Revenue rose 33% in the year to Dec 2025, and grew 23% a year on average over 3 years.
Profit growth
+1514%Net profit rose 1514% in the year to Dec 2025.
Profit margin
6.4%Nephros, Inc. keeps $6 of every $100 of revenue as net profit.
Cash quality
1.4×Cash from Nephros, Inc.'s business was 1.4× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
1146.0×Nephros, Inc.'s operating profit covered its interest costs 1146.0 times in the year to Dec 2025.
Cash vs debt
Net cashNephros, Inc. held $4 M more cash than debt (net cash) at Dec 2025.
Questions
What is Nephros, Inc.'s P/E ratio?
Investors pay $23.5 for every $1 of Nephros, Inc.'s yearly profit, lower than 57% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Nephros, Inc.: $38 M ÷ $12 M (30 Jun 2026) = 3.2.
What is Nephros, Inc.'s return on equity?
Nephros, Inc. earned 16.1% on its shareholders' money over the last year, higher than 88% of Healthcare companies in United States.
How much does Nephros, Inc. owe compared with what it owns?
Nephros, Inc. owes $0.24 for every $1 it owns (low), lower than 67% of Healthcare companies in United States.
Does Nephros, Inc. pay a dividend?
No. Nephros, Inc. does not currently pay a dividend.
Is Nephros, Inc.'s revenue growing?
Revenue rose 33% in the year to Dec 2025, and grew 23% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.